[{"id":"55ee843e-9dcb-4c92-8779-4c34cdfe315c","acronym":"KEYNOTE-890","url":"https://clinicaltrials.gov/study/NCT03567720","created_at":"2021-01-18T17:33:29.655Z","updated_at":"2025-02-25T16:08:03.661Z","phase":"Phase 2","brief_title":"Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC","source_id_and_acronym":"NCT03567720 - KEYNOTE-890","lead_sponsor":"OncoSec Medical Incorporated","biomarkers":" HER-2 • PD-L1 • ER","pipe":" | ","alterations":" PD-L1 negative","tags":["HER-2 • PD-L1 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • Tavo (tavokinogene telsaplasmid)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 10/11/2018","start_date":" 10/11/2018","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-06-01"},{"id":"7661b4bf-26e4-407b-903a-7f38f8d7d0c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01502293","created_at":"2021-01-18T06:18:16.026Z","updated_at":"2024-07-02T16:35:47.973Z","phase":"Phase 2","brief_title":"Trial of pIL-12 Electroporation Malignant Melanoma","source_id_and_acronym":"NCT01502293","lead_sponsor":"OncoSec Medical Incorporated","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tavo (tavokinogene telsaplasmid)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 02/14/2012","start_date":" 02/14/2012","primary_txt":" Primary completion: 03/21/2016","primary_completion_date":" 03/21/2016","study_txt":" Completion: 03/21/2016","study_completion_date":" 03/21/2016","last_update_posted":"2023-05-15"},{"id":"f0d43c41-1ece-4881-b43d-54ff7877742b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02531425","created_at":"2021-01-18T12:14:28.897Z","updated_at":"2024-07-02T16:35:48.002Z","phase":"Phase 1","brief_title":"Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC","source_id_and_acronym":"NCT02531425","lead_sponsor":"OncoSec Medical Incorporated","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tavo (tavokinogene telsaplasmid)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2023-05-15"},{"id":"86c833c5-1bd1-4456-a4f8-3b0c16874085","acronym":"KEYNOTE 695","url":"https://clinicaltrials.gov/study/NCT03132675","created_at":"2021-01-18T15:26:06.079Z","updated_at":"2025-02-25T16:06:08.061Z","phase":"Phase 2","brief_title":"Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment","source_id_and_acronym":"NCT03132675 - KEYNOTE 695","lead_sponsor":"OncoSec Medical Incorporated","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tavo (tavokinogene telsaplasmid)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 143","initiation":"Initiation: 10/03/2017","start_date":" 10/03/2017","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2023-03-27"},{"id":"4fb02dff-a729-4b7b-a9b9-baa9f3a3f437","acronym":"","url":"https://clinicaltrials.gov/study/NCT02493361","created_at":"2021-01-18T12:01:10.054Z","updated_at":"2025-02-25T16:14:53.591Z","phase":"Phase 2","brief_title":"Trial of pIL-12/MK-3475 in Metastatic Melanoma","source_id_and_acronym":"NCT02493361","lead_sponsor":"University of California, San Francisco","biomarkers":" PD-L1 • CD8 • PTPRC","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • PTPRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tavo (tavokinogene telsaplasmid)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 04/26/2018","primary_completion_date":" 04/26/2018","study_txt":" Completion: 03/02/2020","study_completion_date":" 03/02/2020","last_update_posted":"2021-01-06"}]